APRI (Aprinoia Therapeutics) Current Deferred Revenue: $0.02 Mil (As of Dec. 2023)


What is Aprinoia Therapeutics Current Deferred Revenue?

Aprinoia Therapeutics APRI Current Deferred Revenue is $0.02 Mil as of Dec. 2023.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Aprinoia Therapeutics's current deferred revenue for the quarter that ended in Dec. 2023 was $0.02 Mil.

Aprinoia Therapeutics Current Deferred Revenue Related Terms

Aprinoia Therapeutics Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Aprinoia Therapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprinoia Therapeutics Current Deferred Revenue Chart

Aprinoia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Current Deferred Revenue
0.09 0.21 0.02

Aprinoia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue 0.09 0.00 0.21 0.02 0.02
What does a Current Deferred Revenue of $0.02 Mil mean?
Aprinoia Therapeutics (APRI) has a Current Deferred Revenue of $0.02 Mil as of Dec. 2023. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Aprinoia Therapeutics and its competitors.
Is Aprinoia Therapeutics' Current Deferred Revenue too high?
Aprinoia Therapeutics' current Current Deferred Revenue is $0.02 Mil.
How does Aprinoia Therapeutics' Current Deferred Revenue compare to ?
Aprinoia Therapeutics' Current Deferred Revenue of $0.02 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Aprinoia Therapeutics and its competitors. Aprinoia Therapeutics's current Current Deferred Revenue is $0.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprinoia Therapeutics stock overvalued right now?
Aprinoia Therapeutics (APRI) has a current Current Deferred Revenue of $0.02 Mil. The current Current Deferred Revenue is $0.02 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Aprinoia Therapeutics (APRI), the current Current Deferred Revenue is $0.02 Mil as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprinoia Therapeutics Business Description

Comparable Companies
Address 245 Main Street, 2nd Floor, Cambridge, MA, USA, 02142
Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.